Please ensure Javascript is enabled for purposes of website accessibility

Can Pfizer's Stock Keep Climbing?

By Jim Halley – May 16, 2020 at 7:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This may be a good buying opportunity for a sleeping pharmaceutical giant that should rise this year.

The big news regarding Pfizer (PFE -0.61%) these days centers on its search for a COVID-19 vaccine, but that just obscures more important news for investors. This solid, 171-year-old, diversified pharmaceutical company with more than 88,000 employees looks to have a nice surprise in store for investors this year -- and it's still priced reasonably.

Of course, coming up with a coronavirus vaccine would be huge

It seems as if every pharmaceutical company is working on a COVID-19 vaccine these days, and that includes New York City-based Pfizer.

Doctor holding stethoscope with bubbles of medical logos.

IMAGE SOURCE: GETTY IMAGES

Pfizer is collaborating with German pharmaceutical company BioNTech (BNTX -0.14%) on four vaccine possibilities. Its study will enroll up to 360 human test subjects, and the company said that if any of the treatments are successful, it could begin producing millions of doses of the vaccine this fall. 

There are a lot of ifs, however. None of the vaccines may be successful. Another company might come up with a better vaccine sooner. But it doesn't matter. Pfizer is a huge company with a remarkable stable of drugs, and its pipeline continues to produce.

First the bad news

Its first-quarter numbers, reported April 28, showed a 8% drop in revenue and a 12% slide in net income compared with the same quarter in 2019. Pfizer's regular pharma division actually saw an 11% rise in revenue, but its Upjohn division, which includes some of its older drugs, saw a 37% decline, some of which came from generic competition to nerve pain drug Lyrica and erectile dysfunction drug Viagra. 

Here's where it gets interesting

However, plans are in the works to combine Upjohn with Mylan (MYL) to form a new company, which would be spun off from Pfizer sometime this summer. Investors who hold Pfizer shares will get 0.12 shares of the new company, Viatris, for every Pfizer share they own. Viatris would be the largest generic pharmaceuticals company in the world; meanwhile, Pfizer's freedom from Upjohn will position it for for stronger earnings growth, with sales of its branded drugs not brought down by declining sales on its generic drugs or trademark drugs facing generic price pressure. It already has several blockbuster drugs, such as Vyndaqel, Ibrance, Xeljanz, Eliquis and Prevnar, that won't face significant patent losses for five years.

On Thursday, the company announced positive results from a second phase 3 study on pneumococcal pneumonia vaccine (NCT03828617). On Friday, it said it was proceeding with a Phase 1b clinical study on PF-06939926, a gene therapy for boys with Duchenne muscular dystrophy that could prove a potential blockbuster drug. 

"Based on the encouraging preliminary efficacy data and manageable safety events from our phase 1b study, we believe we may have a potential breakthrough therapy for boys with Duchenne muscular dystrophy, a devastating disease for which there remains a significant medical need," said Seng Cheng, the chief scientific officer in Pfizer's Rare Disease Research Unit. 

This presents an opportunity

Pfizer has 10 consecutive years of dividend growth and an annualized dividend of $1.52 a share. But despite its age, it continues to progress. It had six new drugs on the market in 2019 and has an incredible 95 in its pipeline. It also should emerge a more profitable company once its spinoff of Upjohn is concluded this summer. At its current price of about $37 a share, it remains well off its 52-week high of $44.56, and with a P/E of 13.54 -- much lower than the industry average -- it offers significant value. 

Jim Halley owns shares of Pfizer. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.16 (-0.61%) $0.27
Viatris Inc. Stock Quote
Viatris Inc.
MYL
BioNTech SE Stock Quote
BioNTech SE
BNTX
$133.60 (-0.14%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.